Sign In
Last checked at 
18 Jul 2008 07:00
ο»Ώ
Β
Hutchison China MediTech LimitedΒ ("Chi-Med")
(AIM: HCM)
Notice ofΒ 2008Β Interim Results
London,Β Friday,Β 18Β JulyΒ 2008:Β Chi-MedΒ will be announcing its interim results for the six months endedΒ 30 June 2008Β onΒ Wednesday,Β 6Β August 2008.
Ends
Enquiries
|
Chi-Med Christian Hogg, CEO |
Telephone: +852 2121 8200 |
|
Citigate Dewe Rogerson Anthony Carlisle David Dible |
Telephone: +44 (0) 20 7638 9571 +44 (0) 7973 611 888 +44 (0) 7967 566 919 |
About Chi-Med
Chi-Med is the holding company of a pharmaceutical and healthcare group focused on traditional Chinese medicine ("TCM") based primarily inΒ ChinaΒ and was admitted to trading on the Alternative Investment Market of the London Stock Exchange in May 2006. Chi-Med operates three core business divisions: 1) China Healthcare - the manufacture, distribution and marketing of pharmaceuticals and health supplements inΒ China; 2) Drug R&D - the discovery and global development of novel drug in the oncology and auto-immune therapeutic areas; and 3) Consumer Products - global retailing and distribution consumer health and personal care products derived from TCM and botanical ingredients.
Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.
Follow the stocks
